Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765653 | 0.98 | ALDH1A1 (0.49) | ALDH1A1MAPK1CYP3A4PSEN1PSEN2 | |
| SCHEMBL4674685 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPK1CYP3A4PSEN1PSEN2 | |
| SCHEMBL2798239 | 0.82 | MAPT (0.50) | ALDH1A1MAPK1CYP3A4PSEN1PSEN2 | |
| SCHEMBL31518328 | 0.82 | NAMPT (0.45) | ALDH1A1HTR2AGSRTXNRD1CYP2C9 | |
| Hydrochloric Acid SCHEMBL5271819 | 0.81 | MAPT (0.49) | ALDH1A1MAPK1CYP3A4PSEN1PSEN2 | |
| SCHEMBL10795117 | 0.81 | APLNR (0.47) | ALDH1A1MAPK1CYP3A4PSEN1PSEN2 | |
| SCHEMBL2148808 | 0.79 | TSHR (0.48) | ALDH1A1CYP3A4MEN1KMT2ACA12 | |
| SCHEMBL9072841 | 0.79 | PIK3C3 (0.42) | HTR2AHTR2CKCNH2GSRTXNRD1 | |
| SCHEMBL1268648 | 0.79 | MMP13 (0.45) | HTR2AGSRTXNRD1PIK3C3 | |
| SCHEMBL2924761 | 0.79 | LMNA (0.46) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | claimed |
| EP-2108012-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-10-14 | — | — | EP | claimed |
| WO-2008099076-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | claimed |
| CN-102884047-B | 2-pyridone compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-25 | — | — | CN | disclosed |
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-2108012-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008099076-A2 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT3, PRMT5, PRMT1 | ALDH1A1 827/4885MAPK1 2376/4885CYP3A4 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.